A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).

Phan, Alexandria T.; Yao, James C.; Fogelman, David R.; Hess, Ken; Ng, C. S.; Bullock, S.; Malinowski, Paige; Regan, Eileen; Kulke, M.

doi:10.1200/jco.2010.28.15_suppl.4001

Cited by 56 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the study failed to achieve statistical significance due to unplanned analyses, a 5.9-month improvement in median progression-free survival was observed (7). The role of VEGF inhibition in pancreatic neuroendocrine tumors is also supported by results of multiple phase II studies using other VEGF tyrosine inhibitors (8,9). A separate phase III study comparing bevacizumab with interferon in advanced carcinoid tumors is also ongoing through the cooperative group SWOG (http://www.swog.org; Protocol Abstract 0518).…”

Section: James C Yao and Alexandria Phanmentioning

confidence: 86%

Overcoming Antiangiogenic Resistance

Yao

Phan

2011

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

Section: James C Yao and Alexandria Phanmentioning

confidence: 86%

Overcoming Antiangiogenic Resistance

Yao

Phan

2011

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Pazopanib is a selective small-molecule TKI that inhibits the VEGFR-1, VEGFR-2, VEGFR-3, PDGF-␣, PDGF-␤, and c-kit tyrosine kinases. A phase II study of 29 patients with PNETs and 22 patients with carcinoids treated with a combination of pazopanib and octreotide LAR showed a response rate of 17% in the PNET group with a median PFS of 11.7 and 12.7 months in the PNET and carcinoid groups, respectively [85]. A combination study of pazopanib with temozolomide is currently underway.…”

Section: Tkismentioning

confidence: 99%

A New Era for the Systemic Therapy of Neuroendocrine Tumors

Eads

2012

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Describe the underlying biology of neuroendocrine tumors including pancreatic neuroendocrine tumors (PNETs) and carcinoids and the importance of these biologic features in the evolution of new drugs for these diseases.2. Cite the historical data regarding the use of cytotoxic agents in the treatment of pancreatic neuroendocrine tumors and carcinoids.3. Explain the significance of recent clinical trials utilizing biologic agents, in particular octreotide, the small molecule tyrosine kinase inhibitor, sunitinib and the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and how these medications have altered the natural history of both pancreatic neuroendocrine tumors and carcinoids.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTCarcinoids and pancreatic neuroendocrine tumors are becoming increasingly common, with the majority of patients presenting with either lymph node involvement or metastatic disease. An improved understanding of the molecular mechanisms involved in these tumors has implicated several pathways that have led to new therapeutic approaches. In this manuscript, we describe the biology of neuroendocrine tumors and approaches to systemic therapy. We review early data regarding the use of cytotoxics and several recent studies employing more targeted approaches that promise to change the standard of care. Specifically, phase III studies indicate that pharmacologic inhibition of the vascular endothelial growth factor pathway with sunitinib, and of the mammalian target of rapamycin pathway with everolimus, appears to have altered the natural history of these diseases. These successes set the stage for further advances in the management of patients with neuroendocrine tumors. The Oncologist 2012; 17:326 -338Correspondence: Neal J. Meropol, M.D.,

show abstract

“…Among 29 pancreatic NET patients, five (17%) experienced PRs. The median PFS times were encouraging in both cohorts (12.7 months in the carcinoid cohort and 11.7 months in the pancreatic NET cohort) [46].…”

Section: Pazopanibmentioning

confidence: 85%

Targeted Therapy in Advanced Well-Differentiated Neuroendocrine Tumors

Raut

Kulke

2011

The Oncologist

View full text Add to dashboard Cite

Treatments for advanced neuroendocrine tumors were, until recently, rather limited. Salvage surgery and liverdirected therapy both have relatively limited impact, and systemic cytotoxic chemotherapy has minimal efficacy. In the absence of other effective treatments, somatostatin analogs have been used for years to control disease and neuroendocrine symptoms, without cytotoxic intent. Advances in targeted therapy for neuroendocrine tumors have opened several potentially new treatment paradigms in the management of these otherwise relatively drugresistant neoplasms. Promising results have emerged from studies evaluating radiolabeled somatostatin analogs and inhibitors of the vascular endothelial growth factor and mammalian target of rapamycin pathways. This article reviews several of the more encouraging developments in this field. The Oncologist 2011;16:286 -295

show abstract

A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).

Cited by 56 publications

References 0 publications

Overcoming Antiangiogenic Resistance

Overcoming Antiangiogenic Resistance

A New Era for the Systemic Therapy of Neuroendocrine Tumors

Targeted Therapy in Advanced Well-Differentiated Neuroendocrine Tumors

Contact Info

Product

Resources

About